 MindMed NASDAQ:MNMD, a drug development company in the psychedelics space, announced on Tuesday that the FDA has allowed an investigational new drug application for a Phase 2b trial on a proprietary LSD analog. Shares from the company peaked at 1.30 and closed the Tuesday trading session at 1.17, marking a 25 increase from the previous day. 